Article
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance
15 May 2017
Abstract excerpt
The estrogen receptor (ER) drives the growth of most luminal breast cancers and is the primary target of endocrine therapy. Although ER blockade with drugs such as tamoxifen is very effective, a major clinical limitation is the development of endocrine resistance especially in the setting of metastatic disease. Preclinical and clinical observations suggest that even following the development of endocrine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.